New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 14, 2014
09:28 EDTGILD, CNCCentene best positioned Medicaid pure play to post Q2 EPS beat, says Sterne Agee
Sterne Agee believes that Centene (CNC) is the best positioned among the health insurance companies focusing on Medicaid to beat the consensus Q2 EPS outlook. The firm thinks that increased revenue from Centene's specialty pharmacy unit may have more than offset its increased costs from Gilead's (GILD) Sovaldi in Q2. The firm keeps a Buy rating on Centene.
News For CNC;GILD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 27, 2015
09:36 EDTGILDActive equity options trading on open
Subscribe for More Information
November 24, 2015
09:37 EDTGILDActive equity options trading on open
Active equity options trading on open: AAPL FB BAC DIS NFLX X YNDX GILD PANW SUNW
November 23, 2015
09:39 EDTGILDActive equity options trading on open
Subscribe for More Information
06:41 EDTGILDGilead granted marketing authorization in EU for Genvoya
Subscribe for More Information
November 20, 2015
08:26 EDTCNCManaged Medicaid names unfairly punished yesterday, says Leerink
Subscribe for More Information
07:40 EDTCNCCentene price reaction does not make sense, says UBS
UBS said the price decline in Centene (CNC) shares on concerns surrounding the insurance exchange business following yesterday's comments from UnitedHealth (UNH) does not make sense. The firm said Centene only covers 156,000 lives via the exchanges and although they are not expecting any improvement next year, they are not expecting any deterioration either. UBS reiterated its Buy rating and $80 price target on Centene shares.
November 19, 2015
19:19 EDTCNCOn The Fly: After Hours Movers
UP AFTER EARNINGS: Intuit (INTU), up 8.1%... Ross Stores (ROST), up 8.2%. ALSO HIGHER: Cabela's (CAB), up 7.5% after Bloomberg reported that the company is receiving takeover interest... Nike (NKE), up 3.4% after announcing a $12B repurchase program, a two-for-one stock split, and that it will raise its dividend... Centene (CNC), up 2.4% after reiterating its fiscal 2015 earnings per share guidance... Universal Insurance (UVE), up 2.7% after announcing a new $10M share repurchase program. DOWN AFTER EARNINGS: Nimble Storage (NMBL), down 36.9%... Mentor Graphics (MENT), down 26.2%... Workday (WDAY), down 5.5%... Wesco Aircraft (WAIR), down 1.4%... Williams-Sonoma (WSM), down 3.7%... Zoe's Kitchen (ZOES), down 3.6%... Momo (MOMO), down 3.3%... Autodesk (ADSK), down 1%... Gap (GPS), down marginally.
17:07 EDTCNCCentene backs FY15 EPS view of $2.84-$2.90, consensus $2.88
Subscribe for More Information
10:23 EDTCNCUnitedHealth selloff on guidance presents buying opportunity, says Leerink
Subscribe for More Information
07:46 EDTCNCOptions expected to be active; UNH AET ANTM CI WCG HUM HNT CNC
Subscribe for More Information
November 18, 2015
09:34 EDTGILDActive equity options trading on open
Subscribe for More Information
November 17, 2015
10:47 EDTGILDBristol-Myers strength attributed to sale chatter
The move higher in shares of Bristol-Myers (BMY) is being attributed by traders to chatter of a sale. The stock is up 2%, or $1.06, to $66.08 in morning trading. The unconfirmed talk has the company possibly approaching Gilead (GILD) about buyout interest. Bristol's market capitalization is just above $110B while Gilead's is just above $150B. Shares of Gilead are up 74c to $104.55.
November 16, 2015
09:04 EDTGILDGilead says Phase 3 Zydelig study shows 'clinical benefit'
Gilead announced that its Phase 3 Study 115 evaluating Zydelig added to standard therapy in previously-treated chronic lymphocytic leukemia patients will be unblinded early. The DMC recommendation is based upon a predefined interim analysis indicating a statistically significant benefit in efficacy for progression-free survival and overall survival in patients receiving Zydelig plus bendamustine and rituximab, compared to those receiving only bendamustine and rituximab. The safety profile of Zydelig was consistent with prior studies. Detailed results from this study will be presented during a late-breaking abstracts session at the Annual Meeting of the American Society of Hematology in Orlando, Florida taking place December 5-8. "The clinical benefit observed in this Phase 3 study adds to the body of evidence demonstrating the potential of Zydelig-containing treatment regimens for patients with previously treated CLL," said Norbert W. Bischofberger, PhD, Gilead's Executive Vice President, Research and Development and Chief Scientific Officer. "We look forward to sharing the detailed scientific data with the hematology community at the upcoming ASH meeting."
November 15, 2015
20:17 EDTGILDGilead presents results from four Phase 3 studies of sofosbuvir/velpatasvir
Subscribe for More Information
15:47 EDTGILDGilead reports data from multiple studies of Viread, TAF, others
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use